First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Sarina A Piha-PaulRavit GevaTira J TanDarren Wt LimCinta HierroToshikiko DoiOsama RahmaAlexander LesokhinJason John LukeJavier OteroLisa NardiAngad SinghAlexandros XyrafasXinhui ChenJennifer MatarazaPhilippe L BedardPublished in: Journal for immunotherapy of cancer (2022)
NCT02740270.